Pulmonary infectious complications of tumor necrosis factor blockade

Infectious Disease Clinics of North America

Volumn 24, Issue 3, 2010, Pages 681-692

  Wallis, Robert S ^a,b,c   Schluger, Neil W ^d  

^a PFIZER INC   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Adalimumab; Etanercept; Granuloma; Infection; Infliximab; Mechanism of action; Tuberculosis; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; ANTIVIRUS AGENT; BCG VACCINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; ETANERCEPT; GLUCOCORTICOID; GOLIMUMAB; INFLIXIMAB; ISONIAZID; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE; RIFAMPICIN; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR; IMMUNOLOGIC FACTOR; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

AMINOTRANSFERASE BLOOD LEVEL; ANKYLOSING SPONDYLITIS; BCG VACCINATION; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; CROHN DISEASE; DIAGNOSTIC VALUE; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEPATITIS B; HUMAN; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; JUVENILE RHEUMATOID ARTHRITIS; LATENT TUBERCULOSIS; LUNG INFECTION; MAXIMUM PLASMA CONCENTRATION; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; RISK REDUCTION; SARCOIDOSIS; SIDE EFFECT; TUBERCULIN TEST; TUBERCULOSIS; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; TUBERCULOSIS, PULMONARY;

HUMANS; IMMUNOLOGIC FACTORS; TUBERCULOSIS, PULMONARY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77955263385     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2010.04.010     Document Type: Review

References (89)

1. Humira prescribing information Available at:, Accessed May 24, 2010. http://www.rxabbott.com/pdf/humira.pdf.
2. Infliximab (Remicade) prescribing information Available at:, Accessed May 24, 2010. http://www.remicade.com/remicade/assets/HCP_PPI.pdf.
3. Baughman R.P., Drent M., Kavuru M., et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006, 174(7):795-802.
4. Rossman M.D., Newman L.S., Baughman R.P., et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006, 23(3):201-208.
5. Saleh S., Ghodsian S., Yakimova V., et al. Effectiveness of infliximab in treating selected patients with sarcoidosis. Respir Med 2006, 100(11):2053-2059.
6. Keystone E., Heijde D., Mason D., et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008, 58(11):3319-3329.
7. Sandborn W.J., Feagan B.G., Stoinov S., et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007, 357(3):228-238.
8. Smolen J., Brezezicki J., Mason D., et al. Efficacy and safety of certolizumab pegol in combination with methotrexate (MTX) in patients with active rheumatoid arthritis despite MTX therapy: results from the RAPID 2 study. Ann Rheum Dis 2007, 66(Suppl 2):187.
9. St Clair E.W., Wagner C.L., Fasanmade A.A., et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46(6):1451-1459.
10. Simponi (golimumab) prescribing information Available at:, Accessed May 24, 2010. http://www.simponi.com/simponi/Prescribing-Information/Prescribing-Information.pdf.
11. Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ?. Semin Arthritis Rheum 2005, 34:12-18.
12. Ucb Cimzia prescribing information Available at:, Accessed May 24, 2010. http://www.cimzia.com/pdf/Prescribing_Information.pdf.
13. Winter T.A., Wright J., Ghosh S., et al. Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn disease: an exploratory study. Aliment Pharmacol Ther 2004, 20(11-12):1337-1346.
14. Enbrel prescribing information Agmen and Wyeth Pharmaceuticals, Thousand Oaks (CA); Madison (NJ). Available at:, Accessed May 24, 2010. http://www.enbrel.com/prescribing-information.jsp.
15. Sandborn W.J., Hanauer S.B., Katz S., et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001, 121(5):1088-1094.
16. Utz J.P., Limper A.H., Kalra S., et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003, 124(1):177-185.
17. Carmona L., Hernandez-Garcia C., Vadillo C., et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003, 30(7):1436-1439.
18. Seong S.S., Choi C.B., Woo J.H., et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 2007, 34(4):706-711.
19. Yamada T., Nakajima A., Inoue E., et al. Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan. Ann Rheum Dis 2006, 65(12):1661-1663.
20. Nardell E.A., Wallis R.S. Here today-gone tomorrow: the case for transient acute tuberculosis infection. Am J Respir Crit Care Med 2006, 174(7):734-735.
21. Coaccioli S., Di Cato L., Marioli D., et al. Impaired cutaneous cell-mediated immunity in newly diagnosed rheumatoid arthritis. Panminerva Med 2000, 42(4):263-266.
22. Wallis R.S., Broder M.S., Wong J.Y., et al. Granulomatous infectious diseases associated with TNF antagonists. Clin Infect Dis 2004, 38(9):1261-1265.
23. Wallis R.S., Broder M.S., Wong J.Y., et al. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 2004, 39:1254-1256.
24. Bergstrom L., Yocum D.E., Ampel N.M., et al. Increased risk of coccidioidomycosis in patients treated with TNF antagonists. Arthritis Rheum 2004, 50(6):1959-1966.
25. Tubach F., Salmon D., Ravaud P., et al. Risk of tuberculosis is higher with antitumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry. Arthritis Rheum 2009, 60(7):1884-1894.
26. Fonseca J.E., Canhao H., Silva C., et al. Acta Reumatol Port 2006, 31(3):247-253. [in Portuguese].
27. Brassard P., Kezouh A., Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 2006, 43(6):717-722.
28. Mines D., Novelli L. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 2007, 44(4):619-620.
29. Subramanyan G.S., Yokoe D.S., Sharnprapai S., et al. Using automated pharmacy records to assess the management of tuberculosis. Emerg Infect Dis 1999, 5(6):788-791.
30. Wallis R.S. Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade. Arthritis Rheum 2008, 58(4):947-952.
31. Plessner H.L., Lin P.L., Kohno T., et al. Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis. J Infect Dis 2007, 195(11):1643-1650.
32. Winthrop K.L., Yamashita S., Beekmann S.E., et al. Mycobacterial and other serious infections in patients receiving antitumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network. Clin Infect Dis 2008, 46(11):1738-1740.
33. Wallis R.S. Mycobacterial disease attributable to tumor necrosis factor-alpha blockers. Clin Infect Dis 2008, 47(12):1603-1605.
34. Strangfeld A., Listing J., Herzer P., et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-α agents. JAMA 2009, 301(7):737-744.
35. Esteve M., Saro C., Gonzalez-Huix F., et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004, 53(9):1363-1365.
36. Michel M., Duvoux C., Hezode C., et al. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. J Rheumatol 2003, 30(7):1624-1625.
37. Ostuni P., Botsios C., Punzi L., et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003, 62(7):686-687.
38. Sakellariou G.T., Chatzigiannis I. Long-term anti-TNFalpha therapy for ankylosing spondylitis in two patients with chronic HBV infection. Clin Rheumatol 2007, 26(6):950-952.
39. Ueno Y., Tanaka S., Shimamoto M., et al. Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B. Dig Dis Sci 2005, 50(1):163-166.
40. Wendling D., Auge B., Bettinger D., et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 2005, 64(5):788-789.
41. Roux C.H., Brocq O., Breuil V., et al. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (Oxford) 2006, 45(10):1294-1297.
42. Ferri C., Ferraccioli G., Ferrari D., et al. Safety of antitumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol 2008, 35(10):1944-1949.
43. Oniankitan O., Duvoux C., Challine D., et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 2004, 31(1):107-109.
44. Wallis R.S. Tumor necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 2008, 8(10):601-611.
45. Di Sabatino A., Ciccocioppo R., Cinque B., et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase-dependent pathway in Crohn's disease. Gut 2004, 53(1):70-77.
46. Kirchner S., Holler E., Haffner S., et al. Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes. Cytokine 2004, 28(2):67-74.
47. Shen C., Assche G.V., Colpaert S., et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 2005, 21(3):251-258.
48. ten Hove T., van Montfrans C., Peppelenbosch M.P., et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002, 50(2):206-211.
49. Van den Brande J.M., Braat H., van den Brink G.R., et al. Infliximab but not etanercept induces apoptosis in lamina propria T lymphocytes from patients with Crohn's disease. Gastroenterology 2003, 124(7):1774-1785.
50. Van den Brande J.M., Koehler T.C., Zelinkova Z., et al. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. Gut 2007, 56(4):509-517.
51. Bruns H., Meinken C., Schauenberg P., et al. Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest 2009, 119(5):1167-1177.
52. Keystone EC. Certolizumab. Presented at the Annual European Congress of Rheumatology. Barcelona (Spain), June 13-16, 2007.
53. Nesbitt A., Fossati G., Bergin M., et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007, 13(11):1323-1332.
54. Bourne T., Fossati G., Nesbitt A. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action. BioDrugs 2008, 22(5):331-337.
55. Saliu O., Sofer C., Stein D.S., et al. Tumor necrosis factor blockers: differential effects on mycobacterial immunity. J Infect Dis 2006, 194:486-492.
56. Scallon B., Cai A., Solowski N., et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002, 301(2):418-426.
57. Brewer M.A., Edwards K.M., Palmer P.S., et al. Bacille Calmette-Guerin immunization in normal healthy adults. J Infect Dis 1994, 170:476-479.
58. Mudido P.M., Guwatudde D., Nakakeeto M.K., et al. The effect of bacille Calmette-Guerin vaccination at birth on tuberculin skin test reactivity in Ugandan children. Int J Tuberc Lung Dis 1999, 3(10):891-895.
59. Behr M.A., Wilson M.A., Gill W.P., et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 1999, 284(5419):1520-1523.
60. Brock I., Weldingh K., Leyten E.M., et al. Specific T cell epitopes for immunoassay-based diagnosis of Mycobacterium tuberculosis infection. J Clin Microbiol 2004, 42(6):2379-2387.
61. Ponce de Leon D., cevedo-Vasquez E., Alvizuri S., et al. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 2008, 35(5):776-781.
62. Lalvani A., Nagvenkar P., Udwadia Z., et al. Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. J Infect Dis 2001, 183(3):469-477.
63. Paimela L., Johansson-Stephansson E.A., Koskimies S., et al. Depressed cutaneous cell-mediated immunity in early rheumatoid arthritis. Clin Exp Rheumatol 1990, 8(5):433-437.
64. Ponce de Leon D., cevedo-Vasquez E., Sanchez-Torres A., et al. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 2005, 64(9):1360-1361.
65. Richards N.M., Nelson K.E., Batt M.D., et al. Tuberculin test conversion during repeated skin testing, associated with sensitivity to nontuberculous mycobacteria. Am Rev Respir Dis 1979, 120(1):59-65.
66. Thompson N.J., Glassroth J.L., Snider D.E.J., et al. The booster phenomenon in serial tuberculin testing. Am Rev Respir Dis 1979, 119(4):587-597.
67. Carmona L., Gomez-Reino J.J., Rodriguez-Valverde V., et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005, 52(6):1766-1772.
68. Gomez-Reino J.J., Carmona L., Angel D.M. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007, 57(5):756-761.
69. Comstock G.W., Baum C., Snider D.E. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the Bethel isoniazid studies. Am Rev Respir Dis 1979, 119(5):827-830.
70. IUAT Committee on Prophylaxis Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ 1982, 60(4):555-564.
71. Gordin F.M., Matts J.P., Miller C., et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med 1997, 337(5):315-320.
72. Hawken M., Nunn P., Gathua S., et al. Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya. Lancet 1993, 342(8867):332-337.
73. Pape J.W., Jean S.S., Ho J.L., et al. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993, 342(8866):268-272.
74. Whalen C.C., Johnson J.L., Okwera A., et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med 1997, 337(12):801-808.
75. Edwards L.B., Acquaviva F.A., Livesay V.T. Identification of tuberculous infected: dual tests and density of reaction. Am Rev Respir Dis 1973, 108:1334-1339.
76. Higuchi K., Harada N., Fukazawa K., et al. Relationship between whole-blood interferon-gamma responses and the risk of active tuberculosis. Tuberculosis (Edinb) 2008, 88(3):244-248.
77. Cooray D.V., Moran R., Khanna D., et al. Screening, rescreening and treatment of ppd positivity in patients on anti-TNF-α therapy. Arthritis Rheum 2008, 58:S546-S547.
78. Arend S.M., Leyten E.M., Franken W.P., et al. A patient with de novo tuberculosis during antitumor necrosis factor-alpha therapy illustrating diagnostic pitfalls and paradoxical response to treatment. Clin Infect Dis 2007, 45(11):1470-1475.
79. Belknap R., Reves R., Burman W. Immune reconstitution to Mycobacterium tuberculosis after discontinuing infliximab. Int J Tuberc Lung Dis 2005, 9(9):1057-1058.
80. Garcia-Vidal C., Rodriguez F.S., Martinez L.J., et al. Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis 2005, 40(5):756-759.
81. Strady C., Brochot P., Ainine K., et al. Tuberculosis during treatment by TNFalpha-inhibitors. Presse Med 2006, 35:1765-1772.
82. Wallis R.S., van Vuuren C., Potgieter S. Adalimumab treatment of life-threatening tuberculosis. Clin Infect Dis 2009, 48(10):1429-1432.
83. Mayanja-Kizza H., Jones-Lopez E.C., Okwera A., et al. Immunoadjuvant therapy for HIV-associated tuberculosis with prednisolone: a phase II clinical trial in Uganda. J Infect Dis 2005, 191(6):856-865.
84. McAllister W.A., Thompson P.J., Al-Habet S.M., et al. Rifampicin reduces effectiveness and bioavailability of prednisolone. Br Med J (Clin Res Ed) 1983, 286(6369):923-925.
85. Blackmore T.K., Manning L., Taylor W., et al. Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction involving the brain, lung, and lymph nodes. Clin Infect Dis 2008, 47(10):e79-e82.
86. Sitapati AM, Kao CL, Cachay ER, et al. Treatment of HIV-related inflammatory cerebral cryptococcoma using adalimumab. Clin Infect Dis 2010, 50(2):e7-10.
87. Wallis R.S., Kyambadde P., Johnson J.L., et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS 2004, 18(2):257-264.
88. Karakousis P.C., Yoshimatsu T., Lamichhane G., et al. Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice. J Exp Med 2004, 200(5):647-657.
89. Wallis R.S. Reconsidering adjuvant immunotherapy for tuberculosis. Clin Infect Dis 2005, 41(2):201-208.